Barclays Capital Boosts Price Target on Vertex Pharmaceuticals (VRTX)

By admin | 6 years ago

Equities research analysts at Barclays Capital (NYSE: BCS) lifted their price target on shares of Vertex Pharmaceuticals (NASDAQ: VRTX) from $44.00 to $77.00 in a research note issued to investors on Tuesday. The firm currently has an “overweight” rating on the stock.

A number of other firms have also recently commented on VRTX. Analysts at Wells Fargo & Co. (NYSE: WFC) upgraded shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note to investors on Tuesday. Separately, analysts at Morgan Stanley (NYSE: MS) upgraded shares of Vertex Pharmaceuticals from an “underweight” rating to an “equal weight” rating in a research note to investors on Tuesday. They now have a $51.00 price target on the stock. Finally, analysts at Needham & Company upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research note to investors on Tuesday. They now have a $65.00 price target on the stock.

Shares of Vertex Pharmaceuticals opened at 64.16 on Tuesday. Vertex Pharmaceuticals has a one year low of $26.50 and a one year high of $64.50. The company has a market cap of $13.529 billion and a P/E ratio of 45.63.

Vertex Pharmaceuticals last issued its quarterly earnings data on Thursday, April 26th. The company reported $0.43 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.57 by $0.14. The company’s quarterly revenue was up 496.5% on a year-over-year basis. On average, analysts predict that Vertex Pharmaceuticals will post $0.72 earnings per share next quarter.

Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.

About the author